MAP2K7 and ovarian serous adenocarcinoma: Precisely, MEK inhibitors have been utilized for the treatment of BRAF-mutated melanoma, KRAS/BRAF-mutated colorectal cancer, hepatocellular carcinoma, low-grade serous ovarian cancer, biliary cancers, and metastatic non-small cell lung cancers.